PCM
PACB icon

Polymer Capital Management’s Pacific Biosciences PACB Stock Holding History

Polymer Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.2K Sell
15,300
-22,258
-59% -$39.8K ﹤0.01% 803
2025
Q4 		$70.2K Buy
+37,558
New +$72.2K 0.01% 736

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Polymer Capital Management's PACB Position: Q1 2026 in Review

Polymer Capital Management reduced its Pacific Biosciences (PACB) stake by 59% in Q1 2026, selling an estimated $39.8K and leaving 15,300 shares worth $20.2K. The position accounts for ﹤0.01% of the portfolio, ranked #803.

Polymer Capital Management first reported a position in PACB in Q4 2025 and has held it in 2 quarters since. The position peaked at $70.2K in Q4 2025. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Polymer Capital Management held 15,300 shares of Pacific Biosciences worth $20.2K as of Q1 2026.
  • Polymer Capital Management sold 22,258 Pacific Biosciences shares in Q1 2026, an estimated $39.8K.
  • Pacific Biosciences made up ﹤0.01% of Polymer Capital Management's portfolio in Q1 2026, its #803 holding.
  • Polymer Capital Management first reported a position in Pacific Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Polymer Capital Management's Pacific Biosciences position peaked at $70.2K in Q4 2025.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Polymer Capital Management's 13F filing for Q1 2026, filed 14 May 2026.